US public health agency the US Food and Drug Administration on Friday announced approval for the new Arikayce drug to treat lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) under the Limited Population Pathway for Antibacterial and Antifungal Drugs, or LPAD pathway, the accelerated approval pathway, fast track, breakthrough therapy, priority review an Qualified Infectious Disease Product (QIDP) designations.
The US FDA has granted approval of Arikayce to Insmed Inc of Bridgewater, NJ.
MAC is a type of nontuberculous mycobacteria (NTM) commonly found in water and soil. The symptoms of MAC include persistent cough, fatigue, weight loss, night sweats and occasionally shortness of breath and coughing up of blood. Arikayce will be used to treat patients with the disease who do not respond to conventional treatment.
Arikayce (amikacin liposome inhalation suspension) is the first drug to be approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs, or LPAD pathway, established by Congress under the 21st Century Cures Act. The Approval under the LPAD pathway may be supported by a streamlined clinical development program. These programs may involve smaller, shorter or fewer clinical trials. As required for drugs approved under the LPAD pathway, labeling for Arikayce includes certain statements to convey that the drug has been shown to be safe and effective only for use in a limited population.
The safety and efficacy of Arikayce, an inhaled treatment taken through a nebulizer, was demonstrated in the company's randomised, controlled clinical trial where patients were assigned to one of two treatment groups. One group of patients received Arikayce plus a background multi-drug antibacterial regimen, while the other treatment group received a background multi-drug antibacterial regimen alone.
According to the US FDA, about 29% of patients treated with Arikayce had no growth of mycobacteria in their sputum cultures for three consecutive months by the sixth month of treatment,compared to 9% of patients who were not treated with Arikayce.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial